ARTICANZ - Beta (ver 0.91)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - target/HIF2a
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
target/HIF2a
9
trial(s) found.
NCT07840001
Curative
Phase 2
Not yet recruiting
Neoadjuvant Belzutifan Plus Pembrolizumab in High-Risk, Locally Advanced Clear Cell Renal Cell Carcinoma (
NEBULA
)
HIF2a inhibitor
anti-PD-1 monoclonal antibody
Clear cell renal cell carcinoma
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
NCT07489495
Advanced
Phase 3
Recruiting
A Phase 3, Randomized, Double-blind, Study of Belzutifan + Zanzalintinib Versus Belzutifan + Placebo in Participants With Advanced RCC Who Have Progressed on or After Both PD-1/L1 and VEGF-TKI Therapies in Sequence or in Combination (LITESPARK-034) (
6482-034
)
HIF2a inhibitor
MET/VEGFR2/AXL/MER inhibitor
placebo
Clear cell renal cell carcinoma
NSW
2109 - North Ryde - Macquarie University Hospital (SUSPENDED)
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre (SUSPENDED)
QLD
4102 - Woolloongabba - Princess Alexandra Hospital (SUSPENDED)
WA
6150 - Murdoch - Fiona Stanley Hospital (SUSPENDED)
NCT07405164
Advanced
Phase 3
Recruiting
A Multicenter, Open-label, Phase 3 Extension Study to Evaluate the Long-term Efficacy and Safety in Participants Who Are Currently on Treatment in a Belzutifan Study (LITESPARK-043) (
6482-043
)
HIF2a inhibitor
Cancer
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2217 - Kogarah - St George Hospital
VIC
3199 - Frankston - Peninsula Health Frankston Hospital
WA
6009 - Nedlands - One Clinical Research
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT07293351
Advanced
Phase 1 / Phase 2
Recruiting
ROSETTA RCC-208: A Phase 1/2 Open-label, Multi-center, Randomized Study of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal Cell Carcinoma (RCC) (
CA266-0008
)
bispecific PD-L1/VEGFA antibody
+ HIF2a inhibitor
Clear cell renal cell carcinoma
NSW
2065 - St Leonards - GenesisCare North Shore Private Hospital
2109 - North Ryde - Macquarie University Hospital
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
QLD
4029 - Herston - Metro North Hospital and Health Service
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
NCT07227415
Advanced
Phase 1 / Phase 2
Recruiting
AN INTERVENTIONAL PHASE 1B/2 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF PF-08634404 MONOTHERAPY AND IN COMBINATION WITH OTHER ANTICANCER AGENTS IN ADULT PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC RENAL CELL CARCINOMA (
C6461008
)
bispecific PD-1/VEGF antibody
+ HIF2a inhibitor
Clear cell renal cell carcinoma
Kidney cancer
VIC
3168 - Clayton - Monash Medical Centre
QLD
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital
NCT07227402
Curative
Phase 3
Recruiting
A Phase 3, Randomized, Open-label Study of Belzutifan + Zanzalintinib Versus Cabozantinib in Participants With Advanced RCC Who Experienced Disease Recurrence During or After Prior Adjuvant Anti-PD-1/L1 Therapy (
LITESPARK-033
)
AXL/MET/RET/VEGFR/ROS1/KIT inhibitor
AXL inhibitor
HIF2a inhibitor
KIT inhibitor
MET/VEGFR2/AXL/MER inhibitor
MET inhibitor,type 2
RET inhibitor
ROS1 inhibitor
VEGFR2 inhibitor
Clear cell renal cell carcinoma
NSW
2109 - North Ryde - Macquarie University Hospital
NCT07011719
Advanced
Phase 3
Recruiting
A Randomized, Double-Blind, Active-Control, Multicenter Phase 3 Trial of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma (
PEAK-1
)
AXL/MET/RET/VEGFR/ROS1/KIT inhibitor
AXL inhibitor
HIF2a inhibitor
KIT inhibitor
MET inhibitor,type 2
RET inhibitor
ROS1 inhibitor
VEGFR2 inhibitor
placebo
Clear cell renal cell carcinoma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2086 - Frenchs Forest - Northern Beaches Hospital
2109 - North Ryde - Macquarie University Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3021 - St Albans - Western Health - Sunshine Hospital
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3128 - Box Hill - Box Hill Hospital - Eastern Health
3199 - Frankston - Peninsula Health Frankston Hospital
QLD
4032 - Chermside - Icon Cancer Care Chermside
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
SA
5037 - Kurralta Park - Icon Cancer Centre Adelaide
5112 - Elizabeth Vale - Lyell McEwin Hospital
WA
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital
TAS
7000 - Hobart - ICON Cancer Care Hobart
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.3010 - Rotorua - Rotorua Hospital
NZ.3210 - Hamilton - Waikato Hospital
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre
NCT05536141
Advanced
Phase 1
Recruiting
A Phase 1, Open-label, Dose Escalation and Dose Expansion Study, to Investigate the Safety, Tolerability, and Pharmacokinetic Profile of AB521 Monotherapy and Combination Therapies in Participants With Clear Cell Renal Cell Carcinoma and Other Solid Tumors (
ARC-20
)
HIF2a inhibitor
Clear cell renal cell carcinoma
NSW
2031 - Randwick - Scientia Clinical Research Ltd
2050 - Camperdown - Chris O'Brien Lifehouse
VIC
3128 - Box Hill - Box Hill Hospital - Eastern Health
NA
NA
NCT04924075
Advanced
Phase 2
Recruiting
A Phase 2 Study to Evaluate the Efficacy and Safety of Belzutifan (MK-6482, Formerly PT2977) Monotherapy in Participants With Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Advanced Solid Tumors With HIF-2α Related Genetic Alterations (
6482-015
)
HIF2a inhibitor
Gastrointestinal stromal tumour
Pancreatic neuroendocrine tumour
Paraganglioma
Phaeochromocytoma
Solid tumour
NSW
2031 - Randwick - Prince of Wales Hospital
VIC
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (8)
Not yet recruiting (1)
Recruitment Country and State
VIC (7)
NSW (6)
QLD (3)
NZ (2)
WA (2)
SA (1)
TAS (1)
Phase
Phase 1 (1)
Phase 1 / Phase 2 (2)
Phase 2 (2)
Phase 3 (4)
Trial Type
Advanced (7)
Curative (2)
Cancer Therapy Class
HIF2a
100%
AXL
67%
MET
67%
VEGFR2
67%
KIT
67%
VEGFR
67%
PD-1/PD-L1
56%
RET
56%
ROS1
56%
PD-1
44%
CTLA4
33%
MER
22%
VEGF
22%
PD-L1
11%
VEGFA
11%
PDGFR
11%
Facility
2109 - North Ryde - Macquarie University Hospital (4)
3000 - Melbourne - Peter MacCallum Cancer Centre (2)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (2)
3199 - Frankston - Peninsula Health Frankston Hospital (2)
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research (2)
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (2)
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (2)
2050 - Camperdown - Chris O'Brien Lifehouse (2)
3128 - Box Hill - Box Hill Hospital - Eastern Health (2)
4102 - Woolloongabba - Princess Alexandra Hospital (1)
6150 - Murdoch - Fiona Stanley Hospital (1)
2217 - Kogarah - St George Hospital (1)
6009 - Nedlands - One Clinical Research (1)
2065 - St Leonards - GenesisCare North Shore Private Hospital (1)
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre (1)
4029 - Herston - Metro North Hospital and Health Service (1)
3168 - Clayton - Monash Medical Centre (1)
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital (1)
2086 - Frenchs Forest - Northern Beaches Hospital (1)
3021 - St Albans - Western Health - Sunshine Hospital (1)
4032 - Chermside - Icon Cancer Care Chermside (1)
5037 - Kurralta Park - Icon Cancer Centre Adelaide (1)
5112 - Elizabeth Vale - Lyell McEwin Hospital (1)
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital (1)
7000 - Hobart - ICON Cancer Care Hobart (1)
NZ.3010 - Rotorua - Rotorua Hospital (1)
NZ.3210 - Hamilton - Waikato Hospital (1)
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre (1)
2031 - Randwick - Scientia Clinical Research Ltd (1)
NA
2031 - Randwick - Prince of Wales Hospital (1)
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health (1)
Cancer Type
Cancer
Solid tumour
Clear cell renal cell carcinoma
Kidney cancer
Urogenital cancer
Adrenal cancer
Endocrine gland cancer
Gastro-entero-pancreatic neuroendocrine tumour
Gastrointestinal cancer
Gastrointestinal stromal tumour
Neuroendocrine tumour
Pancreatic cancer
Pancreatic neuroendocrine tumour
Pancreatobiliary cancer
Paraganglioma
Phaeochromocytoma
Upper gastrointestinal cancer
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy